Prolactin Receptor Isoforms Expression and Activation of STAT5 in Lung Cancer Cell Lines: Its Possible Association with Carcinogenesis

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines - Silexion Therapeutics (NASDAQ:SLXN)

Grand Cayman, Cayman Islands, July 09, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced new positive preclinical data demonstrating SIL204's significant efficacy in human lung cancer cell lines. The Company is also pleased to announce that it is in the process of conducting …

Prolactin receptor isoforms expression and activation of STAT5 in lung cancer cell lines: its possible association with carcinogenesis

BackgroundIn the last years, it has been noticed the participation of prolactin in different malignancies such as breast and prostate cancer. Recently, prolactin (PRL) was proposed as a biomarker for lung cancer but its molecular mechanisms remain to be explored in this tissue. T...